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ABSTRACT 
PPCM is an idiopathic cardiomyopathy presenting with heart failure secondary to left ventricular 
systolic dysfunction towards the end of the pregnancy, or in the months following delivery, where no 
other cause for heart failure is found. Outcome varies from full recovery, to residual left ventricular 
systolic dysfunction and even death. Many women return to their physician to acquire information 
on their long-term prognosis, to seek medical advice regarding contraception or when planning a 
subsequent pregnancy. This position paper summarizes the current evidence for long-term outcome, 
risk stratification of further pregnancies and overall management.  Based on the best available 
evidence, as well as the clinical experience of the Study Group members, a consensus on pre- and 
postpartum management algorithms for women undergoing a subsequent pregnancy is presented.  
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INTRODUCTION 
Peripartum Cardiomyopathy (PPCM) is an idiopathic form of cardiomyopathy, presenting with heart 
failure secondary to left ventricular dysfunction towards the end of pregnancy or in the months 
following delivery, where no other cause of heart failure is identified.1 Patients can present with 
severe acute heart failure with a high morbidity and mortality requiring a multi-disciplinary 
approach.2 Even those who present with more subtle symptoms can still have long-term impaired 
cardiac function.3 Until recently, data on suspected or confirmed cases of PPCM from Europe and 
most other regions of the world were limited. However, data from the ongoing EurObservational 
Research Registry on PPCM4 have shown that this condition occurs globally.5 Patients with PPCM are 
often young, have just started their families and, often, wish to fall pregnant again.  The impact of a 
subsequent pregnancy on clinical outcome is crucial,6 as it will not only affect the pregnant woman, 
but also other family members such as her partner and other children under their care. Moreover, 
after the traumatic experience of PPCM patients may also develop psychological disorders that need 
treatment. 
 
WHAT IS KNOWN ABOUT THE LONG-TERM OUTCOME OF WOMEN WITH PPCM? 
When a woman is diagnosed with PPCM, questions relating to the long-term consequences of the 
condition commonly arise. Women have described feeling terrified and devastated following a 
diagnosis of PPCM.7 They often struggle with recommendations to avoid a further pregnancy and 
report damaging effects on their marriage and relationships with other family members.7 In a review 
of comments from a PPCM support website, several messages were from users searching for 
information related to recovery, its length of time, the impact of subsequent pregnancies and the 
duration of medical therapy.8 Many studies on PPCM have investigated the clinical course over 6 
months or a year, but few have investigated outcomes over several years or decades.  Women are 
understandably interested not only in outcomes during the early period following a diagnosis, but 
also in the long-term prognosis. Risk prediction of normalization of cardiac function and survival 
beyond 5 years cannot be provided based on solid prospective data. There are also no prospective 
long-term outcome data on larger cohorts of patients with PPCM that have received a left 
ventricular assist devices or cardiac transplantation to make clear recommendations on long-term 
benefit. Much of what we do know comes from small studies of selected populations and from 
restricted geographical areas (Table 1).  
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Long-term Mortality  
1-6 months postpartum 
Outcomes for patients with PPCM appear to be more favourable than for those with other forms of 
cardiomyopathy. In a comparison of mortality, over a mean follow-up period of 4.4 years in a large 
single-centre study of 1230 patients with cardiomyopathy, survival was greater in patients with 
PPCM than in those with idiopathic cardiomyopathy (adjusted HR 0.31, 0.09-0.98).9 Nonetheless, 
despite increasing recognition and understanding of PPCM, mortality rates have only been studied in 
a small number of countries and most available data comes from the USA, South Africa, Haiti, Turkey 
and Pakistan. There are very few studies from Europe which report outcomes for women with PPCM 
and these are mainly small case series of n≤12.10-13 Most studies to-date have concentrated on 
mortality at 6 months, with a wide variation in reported rates, ranging from 2% in Germany10 to 
12.6% in a large cohort of 206 patients with PPCM from South Africa.14 Our current focus is on 
outcomes beyond 6 months.   
6-12 months postpartum 
Mortality up to 12 months is 4-14%, with the majority towards the lower end of this range (Table 1). 
The highest rates of mortality at 6-12 months are seen in African women (12-14%).15,16 This racial 
variation is evident elsewhere. For example, in the IPAC study in the United States (30% self-
designated black), mortality at 12 months was 4%17 while, in Detroit, (96% were African-American 
women) 11% died at a median follow-up of 12.5 months.18 A recent trial adding the prolactin blocker 
bromocriptine on top of standard therapy for heart failure reported an excellent 6 months follow-up 
outcome in severely diseased patients having over 60% full recovery and 0% mortality, heart 
transplantation and/or use of assist device.19  
1-5 years postpartum 
Of 182 women from the USA (56% Caucasian, 29% African-American, 10% Hispanic, 3% Asian), 
mortality was 7% at a mean follow-up of 19 months.20 A significantly larger proportion of the group 
who died or underwent cardiac transplantation were non-Caucasian, compared with the rest of the 
group (76% vs. 39%, p=0.0001). At around 2 years, studies of black populations report mortality of 
28% in South Africa,21 16% in Louisiana, USA22 and 15% in Haiti.23 Similarly, in a small case series of 
13 women from New York, of which 69% were non-Caucasian, 23% of women had died at 2.1 years24 
In other studies from the USA, outcomes for women with PPCM are more favourable, with 2-year 
mortality of 0-9%.25,26 Mortality is also lower in women with PPCM from Brazil (8% at 2.1 years),27 
and China (4% at 2.3 years). 28 Mortality between 2-5 years varies even more considerably, ranging 
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from 0-6% in French and American women9,11,29-32 to 15-30% in women from China,33, Brazil,34, 
Turkey,35-37, South Africa,38 and the Philippines.39   
Beyond 5 years postpartum 
There are few data beyond 5 years for women with PPCM. In 3 studies from the USA mortality 
ranges from 7-16% at between 7 and 8.6 years.9,40,41 In India, mortality was 23% at 6.1 years42 and in 
Malaysia (n=12) 8.3% at 6.4 years.43 In a prospective study of 181 Nigerian women with PPCM from 
1989, 26% had died at 10 years.44 There are no more recent studies of mortality beyond 5 years in 
African women. 
 
Predictors of late mortality and mode of death 
As recently highlighted by Sliwa et al45 late maternal death (> 42 days postpartum) is globally poorly 
reported despite being an ICD10 coding recommendation. Few studies on PPCM with follow-up 
extending beyond 2 years have sought to identify prognostic indicators in women with PPCM. In 
Turkey baseline LVEF and LV end systolic diameter were identified as significant predictors of 
mortality due to heart failure.35 These results conflict with other long-term follow-up studies, in 
which there were no differences in baseline echocardiographic parameters between deceased and 
surviving study participants.1,22  
While much of the existing data suggest that the risk of death is greatest in the early postpartum 
period, later deaths occurring either due to deterioration of cardiac function or arrhythmia have 
been noted.  Only 36% of deaths occurred within 6 months in a group of 80 women with PPCM from 
South Africa, with a further 36% at 6-12 months and 27% at 12-24 months.21 Notably, in this 
cohort,21 recovery of LV function had occurred in 29% of patients who died between 6-24 months, 
suggesting that even in those with early recovery, a risk of mortality persisted beyond this.21  In a 
retrospective 2-centre study of 100 women from the USA, 2 out of 11 women who died had 
recovered LV function by a mean of 23 months and death occurred at a mean of 83 months.40 In fact 
more recent data using wearable cardioverter/defibrillator (WCD) clearly demonstrate a high risk for 
ventricular tachyarrhythmias (VTA), and sudden death in patients with PPCM is more common in the 
acute phase of the disease but may even occur during recovery.46,47 In general the recommendations 
of the ESC Guidelines for acute and chronic heart failure on the on the use of wearable 
cardioverter/defibrillators should be followed48.  
However, clear markers to identify patients at risk for arrhythmic death or non-sudden death do not 
exist. Consequently, although the time at which death occurs following a diagnosis of PPCM is clearly 
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important with regard to informing patients and also to decide whether or not continued 
pharmacological or device therapy may be warranted, more research to identify prognostic factors 
or markers associated with late death in women with PPCM is needed. 
 
Recovery of left ventricular (LV) function 
Recovery at 6 months 
Studies of recovery of cardiac function with an echocardiographic left ventricular ejection fraction 
(LVEF) >45% have largely focussed on the trajectory over the first 6 months postpartum and rates 
vary markedly from one country to another. Six-month recovery rates between 46-63% have been 
reported in Japan,49 China,50, Turkey,35 Germany,10 and the USA25. Six-month recovery is worse (21-
36%) in South Africa,51,52 Nigeria,53 Pakistan,54 and the Philippines.39  
Recovery beyond 6 months 
Although data on early recovery of LV function is more frequently reported, the concept of 
myocardial recovery beyond 6 months is increasingly recognised. In the recent Investigations of 
Pregnancy-Associated Cardiomyopathy (IPAC) study, a prospective multicentre American study of 
100 women with PPCM, recovery (LVEF>50%) was seen in 72% of women at 12 months.17 Rate of 
recovery between 6 and 12 months is unavailable. In a prospective analysis of a group of 42 Turkish 
women with PPCM, recovery of LV function beyond 6 months was seen in 44%.35 Of those who 
recovered, 60% did so beyond 12 months, with recovery seen up to 42 months postpartum. 
Similarly, a median time to recovery of 54 months was reported in a retrospective analysis of 44 
women with PPCM in Louisiana, USA, with a 30% non-recovery rate reported up to 9 years after 
diagnosis.22 Recovery at 6-monthly intervals, up to 36 months, was also illustrated in a cohort of 116 
women from Haiti, with 28% of all women regaining good cardiac function.55 At each follow-up 
interval, there was a steady increase in the proportion of women who demonstrated recovery of LV 
function. 53% of recovered patients did so beyond 18 months. 
These data illustrate that recovery can occur after 6 months and continuing recovery can be seen, at 
least in some countries, after several years. However, the current literature is far from 
comprehensive. More prospective, multicentre studies of myocardial recovery in unselected 
populations with long-term follow-up are required in order to describe the natural history of cardiac 
function in women with PPCM. More sophisticated echocardiographic investigation, including strain 
measurements and cardiac magnetic resonance imaging, would allow more detailed assessment of 
cardiac function and structure following a diagnosis. To date, recovery of cardiac function has 
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focussed on LVEF and the long-term effects on right ventricular function have not been studied.   
There is a need to investigate the long-term effects on mitral incompetence and if PPCM are left 
with a residual myocardial scar.  
 
DOES MYOCARDIAL FUNCTION DETERIORATE AFTER STOPPING MEDICAL THEPAPY FOR PPCM 
WITH RECOVERED CARDIAC FUNCTION? 
A common clinical question when myocardial recovery occurs in PPCM is: “Should medical therapy 
be stopped?” There are few data to guide this decision and, therefore, no recommendations within 
current guidelines exist. In a prospective, 2-centre study from Turkey investigating recovery in 42 
patients with PPCM, 4 patients (2 who had full recovery of LV function and 2 who had partial 
recovery of LV function) showed delayed deterioration at 12, 24, 26 and 34 months after diagnosis.35 
In the 2 patients who had fully recovered, medication was discontinued when cardiac function 
improved, although the time at which medical therapy was stopped is not clear. The other 2 patients 
were still receiving heart failure therapy. The only other observational study is a cohort of women 
from North Carolina with recovered myocardial function.29 Of the 5 patients who had discontinued 
treatment with both beta-blocker and angiotensin converting enzyme inhibitor, none demonstrated 
deterioration in cardiac function after a mean follow-up of 29 months. There is one further case 
series describing 3 women from the USA with recovered LV function who had a subsequent 
deterioration of myocardial function (unrelated to a further pregnancy) ‘several months or years’ 
later.20 Whether these women were still receiving medical therapy is not reported. Therefore, 
studies evaluating criteria for treatment duration (clinical signs, biomarkers) to determine the time 
and composition of long-term treatment are needed. 
 
WHAT CAN BE RECOMMENDED FOR THE LONG-TERM MANAGEMENT OF WOMEN WITH PPCM? 
The current recommendation, based on consensus of the PPCM HFA Study Group members, is a six-
monthly visit including echocardiography in all women until they recover to an LVEF>50%. In women 
with LV recovery who remain stable after tapering of heart failure drug therapy an annual visit is 
recommended for up to 10 years.   
Patients with persistently reduced EF should continue treatment with ACE inhibitors, beta blockade 
and with mineralocorticoid receptor antagonist (MRA) for example ivabradine and 
sacubitril/valsartan according to the current ESC Guidelines for acute and chronic heart failure.48 
There is no consensus as to whether heart failure medication can be stopped in women with a 
HFA PPCM Subsequent Pregnancy    
Feb 2018_Revision3track 
 
8 
 
recovered left ventricular function or subclinical dysfunction.   However, weaning from medication 
should be performed sequentially with careful and close monitoring of patients clinical and cardiac 
performance (see table 2, Hilfiker-Kleiner/Bauersachs, EHJ 2015).3 Some of the Study Group 
members recommend life-long heart failure therapy at highest dose tolerated based on the fact that 
deterioration of left ventricular function has been observed in women with normalized cardiac 
function. If patients display signs of incomplete recovery despite recovered EF such as persistent LV 
dilatation or reduced myocardial strain, continuation of heart failure drugs (ACE inhibitor, 
betablocker, MRA) should be considered. Research in this field is urgently needed via carefully 
conducted studies. Genetic testing may be considered in patients with a family history for 
cardiomyopathy, as recent studies showed that 15% of PPCM patients carry cardiomyopathy-causing 
mutations. The presence of TTN truncating variants was significantly correlated with a lower ejection 
fraction at one year follow up 56, features important for long-term therapy concepts.  
 
HOW CAN PATIENTS BE BEST ADVISED ABOUT THE RISKS FOR A SUBSEQUENT PREGNANCY?  
Data on subsequent pregnancies in women with a previously diagnosed PPCM are limited. Table 2 
summarizes the studies of women who had a subsequent pregnancy (SSP) after being diagnosed 
with PPCM. However, the mode of data collection is highly variable with some studies not reporting 
the ejection fraction of the index pregnancy, nor the cardiac dimensions, left and right ventricular 
function at the onset of the subsequent pregnancy. Also the date of the last assessment post SSP is 
highly variable.  Therefore, there are enormous gaps in our knowledge. Uri Elkayam recently 
summarized the available information related to SSP in women with a history of PPCM.57 One of the 
largest studies to date, published in the New England Journal of Medicine in 2001, was based on 
information of 44 women with PPCM and SSP, collected via a retrospective survey of members of 
the American College of Cardiology. Twenty-eight of these women had a recovered cardiac function, 
while 16 pregnancies occurred in women with persistent left ventricular dysfunction. All pregnancies 
were associated with a reduction of mean left ventricular ejection fraction (from 49.9+12 % to 42+13 
%, p<0.001), with no mortality in women with normalized EF at onset of a SSP (versus 19% in those 
women who had impaired systolic function (EF 32.0 + 2%) at onset of a SSP (p=0.06). In the same 
study, frequency of premature delivery (11 % versus 37%) and therapeutic abortions (4% versus 
25%) was also greater in women with impaired versus recovered cardiac function at onset of SSP. As 
these data were collected via a retrospective survey, information on medical therapy provided 
during pregnancy was not available. 
A recently published prospective study reported the management and outcome of SSPs in 34 PPCM 
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patients in Germany, Scotland and South Africa.6 Persistently reduced LVEF (<50%) prior to entering 
SSP was present in 47%, while full recovery (LVEF ≥50%) was present in 53% of patients. The 
majority of these patients were of African ethnicity (75%). Overall relapse rate (LVEF < 50% or death 
after at least 6 months follow-up) was 56% with 12% (4/34) mortality). All 4 deaths occurred in the 
women with persistently reduced LVEF prior to SSP. Patients obtaining standard therapy for heart 
failure, and bromocriptine immediately after delivery, displayed significantly better LVEF at follow-
up and a higher rate of full recovery, with no patient dying, compared to patients obtaining standard 
therapy for heart failure alone. This was independent of African or Caucasian race. Bromocriptine 
was provided to a number of patients, based on previous research suggesting that the nursing 
hormone, prolactin, which is highly elevated during delivery, and periodically in nursing mothers, is a 
key player in the pathophysiology of PPCM.58  A number of factors, such as oxidative stress, promote 
the cleavage of prolactin in an antiangiogenic 16kDa-PRL fragment being causally involved in 
PPCM.59 Furthermore, experimental studies in mice and small clinical pilot studies suggest a 
beneficial effect of the prolactin blocker bromocriptine to improve outcome of acute PPCM60 or 
prevent relapse after a SSP.6  Recent data from the EuroObs PPCM global registry has demonstrated 
that of 411 patients, 21.1% received bromocriptine in their index pregnancy.5  However, 
breastfeeding should be encouraged in women with mild cardiac dysfunction, particularly in areas of 
poor sanitation and unsafe water supply.  
Based on published data 57,6  and consensus by the HFA PPCM Study Group our position is that full 
recovery of LVEF before a SSP is associated with lower mortality and better cardiac function at 
follow-up. However, all patients have a risk of deterioration of cardiac function. Women with 
impaired LV function at the onset of a SSP have a high risk of relapse, heart failure and death and 
pregnancy should be avoided.  
Data have shown that patients with a history of PPCM could have subclinical cardiac dysfunction61,62 
demonstrated reduced myocardial strain after recovery in women with PPCM at least 12 months 
after the diagnosis. There are no published data on the impact on subsequent pregnancy in this 
group of patients.  
Addition of bromocriptine to standard therapy for heart failure immediately after delivery was found 
to be safe and seemed to be associated with a better outcome of SSPs in African and Caucasian 
patients.  
The current recommendation based on published data 57,6    and consensus of the HFA PPCM Study 
Group members on the management of pregnancy and postpartum period in women with a 
previous PPCM is summarized in Figure 1. 
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Patients can be stratified according to impaired or recovered left ventricular function at onset of 
subsequent pregnancy. However, each case would need to be assessed by a multidisciplinary team, 
which includes a cardiologist, obstetrician, neonatologist, anaesthetist and possibly other specialists. 
Neonatologists could provide advice on neonatal outcome if delivery needs to occur prematurely. 
Anaesthetists need to provide input in patients delivering with symptoms and signs of heart failure.  
In addition, overall health system factors and maternal factors such as e.g. age and sub-clinical 
thyroid disease need to be considered.  
In pregnant women renin-angiotensin receptor inhibitors need to be terminated because of fetal 
toxicity. In addition Hydralazine/nitrate combination should be used instead of angiotensin blockers 
for management of heart failure as well prevention of further deterioration.63 Anticoagulation with 
low molecular weight heparin during pregnancy in PPCM women with LV dysfunction should be 
considered.  
In terms of pregnancy from an obstetric standpoint, scans for fetal growth should be performed 
every 4 weeks from week 24. Timing of the delivery, for obstetric reasons, should be driven by the 
usual parameters including fetal growth restriction or pre-eclampsia. For cardiac reasons, early 
delivery should be considered with deteriorating cardiac function and particularly with heart failure. 
Ideally the target would be to reach 37 weeks. However, the best compromise will be achieved by 
discussion with the multidisciplinary team to balance maternal health and fetal maturity.  
Figure 2. Provides a check box for all women with a diagnosis of a PPCM - either newly diagnosed or 
with a PPCM and subsequent pregnancy. Anticoagulation for 6-8 weeks after the delivery could be 
considered because of the hypercoagulability during this period of time. 
 
Contraception for women with a recent PPCM and for patients at high risk in a subsequent 
pregnancy 
Contraceptive counselling should begin early – i.e. as soon as PPCM has been diagnosed. A review on 
the use of contraceptives in women with heart disease has been published recently by Roos-
Hesselink and colleagues.64 Types of the most commonly used contraceptives are summarized in 
Figure 3. Appropriate advice may be complex and will require the input of both a cardiologist and an 
obstetrician to identify the optimal approach. As no studies have been performed in women with 
heart disease, and in particular in women with PPCM, the relative risks and benefits of different 
contraceptive methods are based on consensus only.  As women with PPCM with LV dysfunction are 
at a substantial risk of thrombo-embolic events,5 hormonal contraceptives with a pro-thrombotic 
effect should be avoided. The risk of venous thrombosis is significantly increased (up to 7-fold) by 
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the oestrogen component in oral contraceptives - irrespective of type of progestin used.  However, 
the risk is in the general population is small in absolute numbers (8-10/10,000 women-years 
exposure).65,66 The risks of using a combined oral contraceptive must be weighed against that of an 
unplanned pregnancy. However, since oestrogen-containing oral contraceptives not only increase 
the risk of venous thrombosis, but also of arterial thrombosis and hypertension,67,68 they are 
contraindicated in with most forms of cardiac disease, particularly those associated with an 
increased venous or arterial thrombotic risk, hypertension or ischaemic heart disease.  Further, given 
that the most effective types of contraception are the long-acting reversible forms (intrauterine 
contraceptive devices or progesterone cutaneous implants) and that they have no prothrombotic 
effects, this group of contraceptives should be advised in most cases. They are at least as effective as 
sterilization, the finality of which some women struggle to accept. The progestogen (etonogestrel), 
implant known as Implanon, has no cardiac effects, is effective and has fewer side-effects, such as 
irregular bleeding, than other implants.64  The progesterone releasing intrauterine system, Mirena, is 
preferred to the older copper IUCDS as the majority of users have no periods. Due to high failure 
rates barrier methods should only be recommended in addition to other contraceptive methods. 
In reaching a decision about type of contraception given the significant maternal morbidity and 
mortality risk of a subsequent pregnancy, the partner of the women should be involved in reaching 
the decision about type of contraception. In the decision making the following issues should be 
considered:  
1)  The risk of pregnancy for the mother and the consequences of an unplanned pregnancy.  
2)  The impact of any pregnancy on the entire family, which could include to hospitalization due 
to heart failure, embolic events and death.  
3)  The risks and benefits of the type of contraception - in particular pro-thrombotic effects.  
4)  Failure rates of the type of contraception.  
5)  The availability and affordability of different types of contraception.   
6)  The individual’s preferences, which may include the option of sterilization for the women or 
her partner. 
7)  For the majority of women, a long-acting reversible form such as an intrauterine 
contraceptive device will be most favourable.  
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CONCLUSION AND WAY FORWARD 
The current evidence for long-term outcome is based mostly on single-centre studies or small 
registries. All patients with a previously diagnosed PPCM and their partners should receive careful 
counselling about the longer-term prognosis and undergo a risk stratification if further pregnancies 
are considered. Patients who undergoing a subsequent pregnancy should be monitored by an 
experienced multi-disciplinary team throughout the pregnancy and for at least 1 year postpartum. 
Based on recently published data, women undergoing a subsequent pregnancy with an impaired 
systolic function are at substantial risk for a relapse and death and should therefore be advised 
against pregnancy. Breastfeeding is not advisable in cases with severely impaired systolic function. In 
those patients inhibition of prolactin with bromocriptine should be considered. The ongoing 
EURObservational Program on PPCM will provide much needed longer-term outcome data.5  
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Table 1: Long-term outcome of patients with PPCM 
Table 2: Studies of PPCM patients undergoing a subsequent pregnancy 
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Figure 1: Counselling of women with PPCM regarding subsequent pregnancy and a guide to 
management. 
Figure 2: Post discharge check box for women diagnosed with PPCM 
Figure 3: Sketch illustrating different types of contraceptives  
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 Table 1. Studies of n≥8 after 1985 describing long-term (> 6 months) mortality in women with PPCM stratified by region 
First author Year Study period Location Study type Number Mean age 
(years) 
Mortality 
(%) 
Follow-up in 
months/years 
(mean or median) 
6-12 months 
Libhaber 2015 2008-2014 South Africa Prospective, 2 centres 206 30 12 6 m 
Hagikhia 2013 2004-2012 Germany, Hannover Prospective, 1 centre 115 34 2 6  m 
Barbosa 2012 NA Brazil Prospective, 1 centre 9 29 0 7.9 m 
Isezuo 2006 2003-2005 Sokoto, Nigeria Prospective, 1 centre 65 28 12 9.7 m 
Desai 1995 1986-1989 Durban, South Africa Retrospective, 1 centre 97 29 14 7  m 
Kamiya 2011 2007-2008 Japan Survey, nationwide 102 32 4  9.4 m 
Ravikishore 1991 NA New Delhi, India Prospective, NA 20 28 5 10 m 
12-23 months 
Briasoulis 2016 2009-2014 Detroit, USA Retrospective, 1 centre 47 29 11 12.5 m 
McNamara 2015 2009-2012 USA Prospective, multicentre 100 30 4 12 m 
Goland 2013 1993-2007 Louisiana + South California, USA Retrospective, 2 centre 156 29 7 19 m 
Goland 2009 NA USA  Retrospective, NA 182 29 7 19 m 
Bernstein 2001 1985-1995 Connecticut + New York, USA Retrospective, 2 centre 23 30 13 12 m 
O’Connell 1986 NA Illinois, USA Prospective, 1 centre 14 28 43 12.1 m 
Carvalho 1989 1982-1988 Sao Paulo, Brazil Prospective, 1 centre 19 26 16 21 m 
Prasad 2014 2006-2012 Maharashtra, India Prospective, 1 centre 16 25 6 12 m 
~ 2 years 
Cooper 2012 2002-2008 USA Prospective, multicentre 39 30 0 2.1 y 
Modi 2009 1992-2003 Louisiana, USA Retrospective, 1 centre 44  25 16 2 y 
Elkayam 2005 1997-1998 USA Survey, American College of 
Cardiology 
100 30 9 2  y 
van Hoeven 1993 1982-1990 New York, USA Retrospective, 1 centre 13 30 23 2.1 y 
Cole 1987 NA Boston, USA Prospective, NA 14 30 7 2 y 
Fett 2005 2000-2005 Haiti Prospective, 1 centre 98  32 15 2.2 y 
Moreira 2005 1994-2002 Sao Paulo, Brazil Retrospective, 1 centre  12 24 8 2.2 y 
Sliwa  2011 2006-2010  Soweto, South Africa Prospective, 1 centre 80 29 28 2 y 
Liu 2016 1983-2014 Beijing, China Retrospective, 1 centre 28 27 4 2.3 y 
2.5-5 years 
Gunderson 2011 1995-2004 North California, USA Retrospective, population 110 NA 2  3 y 
Habli 2008 2000-2006 Ohio + Kentucky, USA Retrospective, 2 centre 70 NA 0 3.4 y 
Brar 2007 1996-2005 South California, USA Retrospective, population 60 33 3 4.7 y 
Amos 2006 1990-2003 North Carolina, USA Retrospective, 1 centre 55 29 0 3.6 y 
Felker 2000 1982-1997 Baltimore, USA Retrospective, 1 centre 51 29 6 5 y 
de Souza 2001 1990-1999 Sao Paulo, Brazil Prospective, 1 centre 29 28 28 3.3 y  
Ntusi 2015 1996-2009 Cape Town, South Africa Prospective, 1 centre 30 31 17 3.5 y 
Li 2016 2004-2011 Beijing, China Retrospective, 1 centre 71 28 0 3.6 y 
Cuenza 2016 2005-2015 Quezon City, Philippines Retrospective, 1 centre 39 28 26  4.5 y  
Akil 2016 2002-2012  Turkey Retrospective, 3 centre 58 31 15 2.7 y  
Table 1 - Longterm outcome
  
Biteker 2012 2005-2009 Istanbul, Turkey Prospective, 2 centre 42 27 24 3.3 y  
Duran 2008 1995-2007 Istanbul, Turkey Prospective + retrospective, 1 centre 33  32 30 4 y 
Mouquet 2012 1999-2006 Lille, France Prospective, 1 centre 8 28 0 4.2 y 
 >5 years 
Pillarisetti 2014 1999-2012 Kansas + Michigan, USA Retrospective, 2 centre 100 30 11 8.2 y 
Harper 2012 2002-2004 North Carolina, USA Retrospective, population 85 NA 17 7 y 
Felker 2000 1982-1997 Baltimore, USA Retrospective, 1 centre 42 29 7 8.6 y  
Adesanya 1989 1969-1972 Zaria, Nigeria Prospective, 1 centre 181 NA 26 10 y 
Chee 2013 2000-2009 Kuala Lumpur, Malaysia Retrospective, 1 centre 12 32 8 6.4 y 
Mishra 2006 1995-2005 Cuttack Orissa, India Prospective, NA 56 31 23 6.1 y 
Lamparter 2007 1989-2003 Marburg, Germany Prospective, registry  10 30 0 5.8 y 
Table 2:  Studies of PPCM patients undergoing a subsequent pregnancy 
 
 
First author 
 
Year Number 
Pregnancies
* 
Post index pregnancy LV function Persistent LVSD post 
subsequent 
pregnancy** 
n (%) 
Maternal death 
Miscarriage/ 
fetal death 
n (%) 
Recovered 
 n (%) 
Unrecovered 
n (%) 
Total death 
n (%) 
Number of deaths in  
unrecovered LV function 
(% of total deaths) 
Suttona 1991 4 4 4 (100) 0 0 0 - 0 
Witlina 1997 6 7 NA NA NA 1 (17) 1 (100) 0 
Albanesi Filhob 1999 12 16 6 (50) 6 (50) NA 1 (8) 1 (100) 0 
de Souzaa 2001 7 7 NA NA 7 (100) 0 - 0 
Elkayamc 2001 44 35 28 (64) 16 (36) 9 (20) 3 (7) 3 (100) 0 
Avilab 2002 18 19 7 (39) 11 (61) 4 (44)^ 1 (6) 1 (100) 0 
Sharieffb 2003 9 NA 2 (22) 7 (78) 5 (56) 2 (22) NA NA 
Sliwad 2004 6 6 2 (33) 4 (67) 5 (83) 2 (33) 2 (100) 0 
Chapaa 2005 6 8 4 (67) 2 (33) 5 (83) 0 - NA 
Fettb 2006 15 16 1 (7) 14 (93) 7 (47) 1(7) NA NA 
Mishra 2006 9 NA NA NA NA 5 (56) NA NA 
Hilfiker-Kleinerb 2007 12 12 12 (100) 0 6  (50) 3 (25) 0 NA 
Habli 2008 37 21 NA NA NA 0 - 0 
Modic 2009 NA 15 4 (27) 11 (73) NA 0 - 6 (40) 
Cheec 2009 2 1  2 (100)  0 NA 0 - 0 
Fette 2010 56 61 29 (52) 27 (48) 9 (15)^^ 1 (2) 1 (100) NA 
Mandalf 2011 6 6 5 (83) 1 (17) 1 (17) 1 (17) 1 (100) 1 (17) 
Hilfiker-Kleinerc 2017 34 31 18 (53) 16 (47) 17 (53)∞ 4 (12) 4 (100) 1 (3) 
* Number without therapeutic abortion **at last follow-up  ^n=9 with follow-up data ^^denominator is number of pregnancies  ∞n=32 with follow-up data 
a Fractional shortening 30% used as cut off b Unknown cut-off  cEF 50% used as cut off d EF 40% used as cut off eEF 55% used as cut off f EF 45% used as cut off 
Table 2 - Subsequent pregnance
Figure 1: Management of women with PPCM and a subsequent pregnancy
Specific management
Pregnancy can continue but some risks 
remain 
• Bromocriptine: consider post partum
• Admission to high-care unit  if in 
decompensated heart failure
PPCM with partially or fully recovered LV 
function (LVEF>50%)
• Substantial  risk of relapse with 
subsequent pregnancy
• Risk of heart failure or death (<10%)
• Usually good fetal outcome
General Maternal Health Factors
• Age < 18 or Age > 35
• Poor maternal education
• Low household income
• Long distance to appropriate care
• Late presentation ( > 20 weeks)
PPCM with poorly recovered LV function 
(LVEF<50%)
• High risk of relapse with subsequent
pregnancy Risk of heart failure or death
(>10%)
• Risk of premature delivery
• Risk of fetal death
Specific management
• Physicians should advise against 
pregnancy especially if LVEF < 30%
• BOARD:
• Bromocriptine : strongly 
consider post partum
• Oral Heart failure 
• Anticoagulation
• Relaxant: vasodilators
• Diuretics
General Management
• Referral to experienced centre
• Careful counselling of risk
• Close monitoring by cardiac-obstetric-
anaesthetic team
• Monthly echocardiograms
• NT-ProBNP monitoring pre- and 
postpartum
• Careful post partum care
• Contraception advice post partum
Figure 1 Click here to download Figure Figure 1 - Management PPCM subsequent_
Rev1Track.ppt
Figure 2:  Post Discharge Check Box for women diagnosed with PPCM
• Adequate post diagnosis counselling, including future 
pregnancies and prognosis
• Counselling and education of families 
• Prescription of formula milk provided if women is not 
breastfeeding
• Adequate dose of heart failure medication
• Contraceptive advice provided
• Referral to appropriate centre if unable to come back to 
expert centre
• Referred to social worker if unable to work/low income 
circumstances
Figure 2 Click here to download Figure Figure 2 - Post discharge check box 31_May
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Figure 3:  Types of contraception
Contraception (Female)
• Intrauterine contraceptive device
(e.g. Mirena or copper IUCDs)
• Oral contraceptive (combined or 
progestin only pills) 
• Depomedroxyprogesterone acetate 
(DMPA) injections
• Tubal ligation
• Diaphragm
• Contraceptive implants
• Contraceptive patch
• Hysteroscopic tubal occlusion (HTO)
• Vaginal ring
• Safe period
Contraception (Male)
• Condom
• Vasectomy
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